Table 1

Patientdemographics

Patient demographics at baseline
Teprotumumab group, N = 10Placebo, N = 12
Age (years), mean (SD)50 (13)59 (7)
Gender, (N)
Male42
Female610
Race, (N)
Caucasian1010
Black00
Asian02
Smokers, (N)24
Months since diagnosis of Graves’ disease, mean (SD)16.4 (20)24.8 (41.3)
Months since diagnosis of TED, mean (SD)5.8 (2.2)6.0 (2.3)
  • TED, thyroid eye disease.